Factors affecting pathological complete response in locally advanced breast cancer cases receiving neoadjuvant therapy: A comprehensive literature review
M Alamoodi - European journal of breast health, 2023 - pmc.ncbi.nlm.nih.gov
Determining pathological complete response (pCR) could be an important step in planning
individual treatment, hence improving the prognosis in terms of survival. Achieving breast …
individual treatment, hence improving the prognosis in terms of survival. Achieving breast …
Racial disparities in breast cancer: from detection to treatment
Abstract Purpose of Review Update on current racial disparities in the detection and
treatment of breast cancer. Recent Findings Breast cancer remains the leading cause of …
treatment of breast cancer. Recent Findings Breast cancer remains the leading cause of …
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry …
Abstract Background Endocrine-resistant HR+/HER2-breast cancer (BC) and triple-negative
BC (TNBC) are of interest for molecularly informed treatment due to their aggressive natures …
BC (TNBC) are of interest for molecularly informed treatment due to their aggressive natures …
Race, gene expression signatures, and clinical outcomes of patients with high-risk early breast cancer
B Kyalwazi, C Yau, MJ Campbell… - JAMA Network …, 2023 - jamanetwork.com
Importance There has been little consideration of genomic risk of recurrence by breast
cancer subtype despite evidence of racial disparities in breast cancer outcomes. Objective …
cancer subtype despite evidence of racial disparities in breast cancer outcomes. Objective …
Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent
The biologic basis of genetic ancestry-dependent variability in disease incidence and
outcome is just beginning to be explored. We recently reported enrichment of a population of …
outcome is just beginning to be explored. We recently reported enrichment of a population of …
Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US
Importance With the increasing delivery of neoadjuvant chemotherapy (NACT) for patients
with breast cancer in the US, it is important to know whether there is differential response to …
with breast cancer in the US, it is important to know whether there is differential response to …
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer
Purpose There are a paucity of data and a pressing need to evaluate response to
neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black …
neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black …
Validation of the RSClin risk calculator in the National Cancer Data Base
AGL Vannier, A Dhungana, F Zhao, N Chen… - Cancer, 2024 - Wiley Online Library
Background Guidelines recommend the use of genomic assays such as OncotypeDx to aid
in decisions regarding the use of chemotherapy for hormone receptor–positive, HER2 …
in decisions regarding the use of chemotherapy for hormone receptor–positive, HER2 …
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach
Background For patients with breast cancer undergoing neoadjuvant chemotherapy (NACT),
most of the existing prediction models of pathologic complete response (pCR) using …
most of the existing prediction models of pathologic complete response (pCR) using …
[HTML][HTML] Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
FPM Rowdo, G Xiao, GF Khramtsova, J Nguyen… - Cancer Letters, 2024 - Elsevier
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with BRCA1/2
mutations, but patients with other mutations may benefit from PARPi treatment. Another …
mutations, but patients with other mutations may benefit from PARPi treatment. Another …